{
  "new_tables": [
    {
      "page": 18,
      "table": [
        {
          "Designation of the\ntherapy": "Medicinal product to be assessed"
        },
        {
          "Designation of the\ntherapy": "Sotorasib",
          "Treatment mode": "Continuously,\n1 x daily",
          "Number of\ntreatments/\npatient/ year": "365.0",
          "Treatment\nduration/\ntreatment\n(days)": "1",
          "Treatment\ndays/ patient/\nyear": "365.0"
        },
        {},
        {
          "Designation of the\ntherapy": "b) Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation\nafter first-line therapy with cytotoxic chemotherapy"
        },
        {},
        {
          "Designation of the\ntherapy": "Docetaxel",
          "Treatment mode": "1 x per 21-day\ncycle",
          "Number of\ntreatments/\npatient/ year": "17.4",
          "Treatment\nduration/\ntreatment\n(days)": "1",
          "Treatment\ndays/ patient/\nyear": "17.4"
        },
        {},
        {
          "Designation of the\ntherapy": "Pemetrexed",
          "Treatment mode": "1 x per 21-day\ncycle",
          "Number of\ntreatments/\npatient/ year": "17.4",
          "Treatment\nduration/\ntreatment\n(days)": "1",
          "Treatment\ndays/ patient/\nyear": "17.4"
        },
        {},
        {
          "Designation of the\ntherapy": "Nivolumab",
          "Treatment mode": "1 x per 14-day\ncycle",
          "Number of\ntreatments/\npatient/ year": "26.1",
          "Treatment\nduration/\ntreatment\n(days)": "1",
          "Treatment\ndays/ patient/\nyear": "26.1"
        },
        {},
        {
          "Designation of the\ntherapy": "Pembrolizumab",
          "Treatment mode": "1 x per 21-day\ncycle",
          "Number of\ntreatments/\npatient/ year": "17.4",
          "Treatment\nduration/\ntreatment\n(days)": "1",
          "Treatment\ndays/ patient/\nyear": "17.4"
        },
        {
          "Treatment mode": "or"
        },
        {
          "Treatment mode": "1 x per 42-day\ncycle",
          "Number of\ntreatments/\npatient/ year": "8.7",
          "Treatment\nduration/\ntreatment\n(days)": "1",
          "Treatment\ndays/ patient/\nyear": "8.7"
        },
        {},
        {
          "Designation of the\ntherapy": "Atezolizumab",
          "Treatment mode": "1 x per 14-day\ncycle",
          "Number of\ntreatments/\npatient/ year": "26.1",
          "Treatment\nduration/\ntreatment\n(days)": "1",
          "Treatment\ndays/ patient/\nyear": "26.1"
        },
        {
          "Treatment mode": "or"
        },
        {
          "Treatment mode": "1 x per 21-day\ncycle",
          "Number of\ntreatments/\npatient/ year": "17.4",
          "Treatment\nduration/\ntreatment\n(days)": "1",
          "Treatment\ndays/ patient/\nyear": "17.4"
        },
        {
          "Treatment mode": "or"
        }
      ]
    },
    {
      "page": 18,
      "table": [
        {
          "Designation of the": "therapy"
        }
      ]
    },
    {
      "page": 18,
      "table": [
        {
          "Number of": "treatments/"
        },
        {
          "Number of": "patient/ year"
        }
      ]
    },
    {
      "page": 18,
      "table": [
        {
          "Treatment": "duration/"
        },
        {
          "Treatment": "treatment"
        }
      ]
    },
    {
      "page": 18,
      "table": [
        {
          "Treatment": "days/ patient/"
        },
        {
          "Treatment": "year"
        }
      ]
    },
    {
      "page": 19,
      "table": [
        {
          "Treatment": "duration/"
        },
        {
          "Treatment": "treatment"
        },
        {
          "Treatment": "(days)"
        },
        {
          "Treatment mode": "1 x per 28-day\ncycle",
          "Number of\ntreatments/\npatient/ year": "13.0",
          "Treatment\ndays/ patient/\nyear": "13.0"
        },
        {},
        {
          "Designation of the\ntherapy": "Docetaxel",
          "Treatment mode": "1 x per 21-day\ncycle",
          "Number of\ntreatments/\npatient/ year": "17.4",
          "Treatment\ndays/ patient/\nyear": "17.4"
        },
        {
          "Designation of the\ntherapy": "Nintedanib",
          "Treatment mode": "2 x on day 2-21\nof a 21-day cycle",
          "Number of\ntreatments/\npatient/ year": "17.4",
          "Treatment\ndays/ patient/\nyear": "348.0"
        },
        {
          "Designation of the\ntherapy": "c) Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation\nafter first-line therapy with an anti-PD-1/PD-L1 in combination with platinum-\ncontaining chemotherapy or after sequential therapy with an anti-PD-1/PD-L1 and\nplatinum-containing chemotherapy"
        },
        {
          "Designation of the\ntherapy": "Patient-individual therapy, taking into account previous therapy and histology with\nselection of afatinib, pemetrexed, erlotinib, docetaxel, docetaxel in combination with\nramucirumab, docetaxel in combination with nintedanib and vinorelbine"
        },
        {
          "Designation of the\ntherapy": "Afatinib"
        },
        {
          "Designation of the\ntherapy": "Afatinib",
          "Treatment mode": "Continuously,\n1 x daily",
          "Number of\ntreatments/\npatient/ year": "365.0",
          "Treatment\ndays/ patient/\nyear": "365.0"
        },
        {},
        {
          "Designation of the\ntherapy": "Pemetrexed",
          "Treatment mode": "1 x per 21-day\ncycle",
          "Number of\ntreatments/\npatient/ year": "17.4",
          "Treatment\ndays/ patient/\nyear": "17.4"
        },
        {},
        {
          "Designation of the\ntherapy": "Erlotinib",
          "Treatment mode": "Continuously,\n1 x daily",
          "Number of\ntreatments/\npatient/ year": "365.0",
          "Treatment\ndays/ patient/\nyear": "365.0"
        },
        {},
        {
          "Designation of the\ntherapy": "Docetaxel",
          "Treatment mode": "1 x per 21-day\ncycle",
          "Number of\ntreatments/\npatient/ year": "17.4",
          "Treatment\ndays/ patient/\nyear": "17.4"
        },
        {},
        {
          "Designation of the\ntherapy": "Docetaxel",
          "Treatment mode": "1 x per 21-day\ncycle",
          "Number of\ntreatments/\npatient/ year": "17.4",
          "Treatment\ndays/ patient/\nyear": "17.4"
        },
        {
          "Designation of the\ntherapy": "Ramucirumab",
          "Treatment mode": "1 x per 21-day\ncycle",
          "Number of\ntreatments/\npatient/ year": "17.4",
          "Treatment\ndays/ patient/\nyear": "17.4"
        },
        {},
        {
          "Designation of the\ntherapy": "Docetaxel",
          "Treatment mode": "1 x per 21-day\ncycle",
          "Number of\ntreatments/\npatient/ year": "17.4",
          "Treatment\ndays/ patient/\nyear": "17.4"
        }
      ]
    },
    {
      "page": 19,
      "table": [
        {
          "Designation of the": "therapy"
        }
      ]
    },
    {
      "page": 19,
      "table": [
        {
          "Number of": "treatments/"
        },
        {
          "Number of": "patient/ year"
        }
      ]
    },
    {
      "page": 19,
      "table": [
        {
          "Treatment": "days/ patient/"
        },
        {
          "Treatment": "year"
        }
      ]
    },
    {
      "page": 19,
      "table": [
        {
          "Patient-individual therapy, taking into account previous therapy and histology with": "selection of afatinib, pemetrexed, erlotinib, docetaxel, docetaxel in combination with"
        }
      ]
    },
    {
      "page": 20,
      "table": [
        {
          "Designation of the\ntherapy": "Nintedanib",
          "Treatment mode": "2 x on day 2-21\nof a 21-day cycle",
          "Number of\ntreatments/\npatient/ year": "17.4",
          "Treatment\ndays/ patient/\nyear": "348.0"
        },
        {},
        {
          "Designation of the\ntherapy": "Vinorelbine",
          "Treatment mode": "1 x every 7 days",
          "Number of\ntreatments/\npatient/ year": "52.1",
          "Treatment\ndays/ patient/\nyear": "52.1"
        }
      ]
    },
    {
      "page": 20,
      "table": [
        {
          "Designation of the": "therapy"
        }
      ]
    },
    {
      "page": 20,
      "table": [
        {
          "Number of": "treatments/"
        },
        {
          "Number of": "patient/ year"
        }
      ]
    },
    {
      "page": 20,
      "table": [
        {
          "Dose/": "patient/",
          "Consumption": "by potency/",
          "Treatment": "days/"
        },
        {
          "Dose/": "treatmen",
          "Consumption": "treatment",
          "Treatment": "patient/"
        },
        {
          "Dose/": "t days",
          "Consumption": "day",
          "Treatment": "year"
        },
        {
          "Designation of\nthe therapy": "Medicinal product to be assessed"
        },
        {
          "Designation of\nthe therapy": "Sotorasib",
          "Dosage/\napplication": "960 mg",
          "Average\nannual\nconsumption\nby potency": "2,920 x 120\nmg"
        },
        {},
        {
          "Designation of\nthe therapy": "b) Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation\nafter first-line therapy with cytotoxic chemotherapy"
        },
        {},
        {
          "Designation of\nthe therapy": "Docetaxel",
          "Dosage/\napplication": "75 mg/m2 =\n142.5 mg",
          "Average\nannual\nconsumption\nby potency": "17.4 x 160 mg"
        },
        {},
        {
          "Designation of\nthe therapy": "Pemetrexed",
          "Dosage/\napplication": "500 mg/mÂ²\n= 950 mg",
          "Average\nannual\nconsumption\nby potency": "34.8 x 500 mg"
        },
        {},
        {
          "Designation of\nthe therapy": "Nivolumab",
          "Dosage/\napplication": "240 mg",
          "Average\nannual\nconsumption\nby potency": "52.2 x 120 mg"
        },
        {},
        {
          "Designation of\nthe therapy": "Pembrolizumab",
          "Dosage/\napplication": "200 mg",
          "Average\nannual\nconsumption\nby potency": "34.8 x 100 mg"
        }
      ]
    },
    {
      "page": 20,
      "table": [
        {
          "Designation of": "the therapy"
        }
      ]
    },
    {
      "page": 20,
      "table": [
        {
          "Dosage/": "application"
        }
      ]
    },
    {
      "page": 21,
      "table": [
        {
          "Dose/": "patient/",
          "Consumption": "by potency/",
          "Treatment": "days/",
          "Average": "annual"
        },
        {
          "Dose/": "treatmen",
          "Consumption": "treatment",
          "Treatment": "patient/",
          "Average": "consumption"
        },
        {
          "Dose/": "t days",
          "Consumption": "day",
          "Treatment": "year",
          "Average": "by potency"
        },
        {
          "Dosage/\napplication": "or"
        },
        {
          "Dosage/\napplication": "400 mg"
        },
        {},
        {
          "Designation of\nthe therapy": "Atezolizumab",
          "Dosage/\napplication": "840 mg"
        },
        {
          "Dosage/\napplication": "or"
        },
        {
          "Dosage/\napplication": "1,200 mg"
        },
        {
          "Dosage/\napplication": "or"
        },
        {
          "Dosage/\napplication": "1,680 mg"
        },
        {},
        {
          "Designation of\nthe therapy": "Docetaxel",
          "Dosage/\napplication": "75 mg/m2 =\n142.5 mg"
        },
        {
          "Designation of\nthe therapy": "Nintedanib",
          "Dosage/\napplication": "200 mg"
        },
        {
          "Designation of\nthe therapy": "c) Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation\nafter first-line therapy with an anti-PD-1/PD-L1 in"
        },
        {
          "Designation of\nthe therapy": "Patient-individual therapy, taking into account prior therapy and histology with selection\nof afatinib, pemetrexed, erlotinib, docetaxel, docetaxel in combination with ramucirumab,\ndocetaxel in combination with nintedanib and vinorelbine."
        },
        {
          "Designation of\nthe therapy": "Afatinib"
        },
        {
          "Designation of\nthe therapy": "Afatinib",
          "Dosage/\napplication": "40 mg"
        },
        {},
        {
          "Designation of\nthe therapy": "Pemetrexed",
          "Dosage/\napplication": "500 mg/mÂ²\n= 950 mg"
        },
        {},
        {
          "Designation of\nthe therapy": "Erlotinib",
          "Dosage/\napplication": "150 mg"
        },
        {},
        {
          "Designation of\nthe therapy": "Docetaxel",
          "Dosage/\napplication": "75 mg/m2 =\n142.5 mg"
        },
        {},
        {
          "Designation of\nthe therapy": "Docetaxel",
          "Dosage/\napplication": "75 mg/m2 =\n142.5 mg"
        },
        {
          "Designation of\nthe therapy": "Ramucirumab",
          "Dosage/\napplication": "10 mg/kg =\n770 mg"
        }
      ]
    },
    {
      "page": 21,
      "table": [
        {
          "Designation of": "the therapy"
        }
      ]
    },
    {
      "page": 21,
      "table": [
        {
          "Dosage/": "application"
        }
      ]
    },
    {
      "page": 21,
      "table": [
        {
          "Patient-individual therapy, taking into account prior therapy and histology with selection": "of afatinib, pemetrexed, erlotinib, docetaxel, docetaxel in combination with ramucirumab,"
        }
      ]
    },
    {
      "page": 22,
      "table": [
        {
          "Dose/": "patient/",
          "Consumption": "by potency/",
          "Treatment": "days/",
          "Average": "annual"
        },
        {
          "Dose/": "treatmen",
          "Consumption": "treatment",
          "Treatment": "patient/",
          "Average": "consumption"
        },
        {
          "Dose/": "t days",
          "Consumption": "day",
          "Treatment": "year",
          "Average": "by potency"
        },
        {},
        {},
        {
          "Designation of\nthe therapy": "Docetaxel",
          "Dosage/\napplication": "75 mg/m2 =\n142.5 mg"
        },
        {
          "Designation of\nthe therapy": "Nintedanib",
          "Dosage/\napplication": "200 mg"
        },
        {},
        {
          "Designation of\nthe therapy": "Vinorelbine",
          "Dosage/\napplication": "25 mg/mÂ² =\n47.5 mg -\n30 mg/mÂ² =\n57 mg"
        }
      ]
    },
    {
      "page": 22,
      "table": [
        {
          "Designation of": "the therapy"
        }
      ]
    },
    {
      "page": 22,
      "table": [
        {
          "Dosage/": "application"
        }
      ]
    },
    {
      "page": 22,
      "table": [
        {
          "Designation of the\ntherapy": "Medicinal product to be assessed"
        },
        {
          "Designation of the\ntherapy": "Sotorasib 120 mg",
          "Packaging\nsize": "240 FCT",
          "Costs\n(pharmacy\nsales price)": "â¬ 4,820.84",
          "Rebate\nSection\n130 SGB\nV": "â¬ 2.00",
          "Rebate\nSection\n130a\nSGB V": "â¬ 466.34",
          "Costs after\ndeduction of\nstatutory\nrebates": "â¬ 4,352.50"
        },
        {
          "Designation of the\ntherapy": "Appropriate comparator therapy"
        },
        {
          "Designation of the\ntherapy": "Atezolizumab 1,200 mg",
          "Packaging\nsize": "1 CIS",
          "Costs\n(pharmacy\nsales price)": "â¬ 4,319.46",
          "Rebate\nSection\n130 SGB\nV": "â¬ 2.00",
          "Rebate\nSection\n130a\nSGB V": "â¬ 417.25",
          "Costs after\ndeduction of\nstatutory\nrebates": "â¬ 3,900.21"
        },
        {
          "Designation of the\ntherapy": "Atezolizumab 840 mg",
          "Packaging\nsize": "1 CIS",
          "Costs\n(pharmacy\nsales price)": "â¬ 3,040.90",
          "Rebate\nSection\n130 SGB\nV": "â¬ 2.00",
          "Rebate\nSection\n130a\nSGB V": "â¬ 292.07",
          "Costs after\ndeduction of\nstatutory\nrebates": "â¬ 2,746.83"
        },
        {
          "Designation of the\ntherapy": "Afatinib 40 mg",
          "Packaging\nsize": "28 FCT",
          "Costs\n(pharmacy\nsales price)": "â¬ 2,515.23",
          "Rebate\nSection\n130 SGB\nV": "â¬ 2.00",
          "Rebate\nSection\n130a\nSGB V": "â¬ 240.61",
          "Costs after\ndeduction of\nstatutory\nrebates": "â¬ 2,272.62"
        },
        {
          "Designation of the\ntherapy": "Docetaxel 160 mg",
          "Packaging\nsize": "1 CIS",
          "Costs\n(pharmacy\nsales price)": "â¬ 515.75",
          "Rebate\nSection\n130 SGB\nV": "â¬ 2.00",
          "Rebate\nSection\n130a\nSGB V": "â¬ 23.94",
          "Costs after\ndeduction of\nstatutory\nrebates": "â¬ 489.81"
        },
        {
          "Designation of the\ntherapy": "Erlotinib 150 mg8",
          "Packaging\nsize": "30 FCT",
          "Costs\n(pharmacy\nsales price)": "â¬ 880.24",
          "Rebate\nSection\n130 SGB\nV": "â¬ 2.00",
          "Rebate\nSection\n130a\nSGB V": "â¬ 68.73",
          "Costs after\ndeduction of\nstatutory\nrebates": "â¬ 809.51"
        },
        {
          "Designation of the\ntherapy": "Nintedanib 100 mg",
          "Packaging\nsize": "120 SC",
          "Costs\n(pharmacy\nsales price)": "â¬ 2,761.26",
          "Rebate\nSection\n130 SGB\nV": "â¬ 2.00",
          "Rebate\nSection\n130a\nSGB V": "â¬ 110.29",
          "Costs after\ndeduction of\nstatutory\nrebates": "â¬ 2,648.97"
        }
      ]
    },
    {
      "page": 22,
      "table": [
        {
          "Designation of the": "therapy"
        }
      ]
    },
    {
      "page": 22,
      "table": [
        {
          "Packaging": "size"
        }
      ]
    },
    {
      "page": 22,
      "table": [
        {
          "Costs": "(pharmacy"
        },
        {
          "Costs": "sales price)"
        }
      ]
    },
    {
      "page": 22,
      "table": [
        {
          "Rebate": "Section"
        },
        {
          "Rebate": "130 SGB"
        },
        {
          "Rebate": "V"
        }
      ]
    },
    {
      "page": 22,
      "table": [
        {
          "Rebate": "Section"
        },
        {
          "Rebate": "130a"
        },
        {
          "Rebate": "SGB V"
        }
      ]
    },
    {
      "page": 22,
      "table": [
        {
          "Costs after": "deduction of"
        },
        {
          "Costs after": "statutory"
        },
        {
          "Costs after": "rebates"
        }
      ]
    },
    {
      "page": 23,
      "table": [
        {
          "Designation of the\ntherapy": "Nivolumab 120 mg",
          "Packaging\nsize": "1 CIS",
          "Costs\n(pharmacy\nsales price)": "â¬ 1,546.93",
          "Rebate\nSection\n130 SGB\nV": "â¬ 2.00",
          "Rebate\nSection\n130a\nSGB V": "â¬ 145.81",
          "Costs after\ndeduction of\nstatutory\nrebates": "â¬ 1,399.12"
        },
        {
          "Designation of the\ntherapy": "Pembrolizumab 100 mg",
          "Packaging\nsize": "1 CIS",
          "Costs\n(pharmacy\nsales price)": "â¬ 2,974.79",
          "Rebate\nSection\n130 SGB\nV": "â¬ 2.00",
          "Rebate\nSection\n130a\nSGB V": "â¬ 285.60",
          "Costs after\ndeduction of\nstatutory\nrebates": "â¬ 2,687.19"
        },
        {
          "Designation of the\ntherapy": "Pemetrexed 500 mg",
          "Packaging\nsize": "1 CIS",
          "Costs\n(pharmacy\nsales price)": "â¬ 572.64",
          "Rebate\nSection\n130 SGB\nV": "â¬ 2.00",
          "Rebate\nSection\n130a\nSGB V": "â¬ 26.64",
          "Costs after\ndeduction of\nstatutory\nrebates": "â¬ 544.00"
        },
        {
          "Designation of the\ntherapy": "Ramucirumab 500 mg",
          "Packaging\nsize": "1 CIS",
          "Costs\n(pharmacy\nsales price)": "â¬ 2,141.31",
          "Rebate\nSection\n130 SGB\nV": "â¬ 2.00",
          "Rebate\nSection\n130a\nSGB V": "â¬ 204.00",
          "Costs after\ndeduction of\nstatutory\nrebates": "â¬ 1,935.31"
        },
        {
          "Designation of the\ntherapy": "Ramucirumab 100 mg",
          "Packaging\nsize": "1 CIS",
          "Costs\n(pharmacy\nsales price)": "â¬ 441.14",
          "Rebate\nSection\n130 SGB\nV": "â¬ 2.00",
          "Rebate\nSection\n130a\nSGB V": "â¬ 40.80",
          "Costs after\ndeduction of\nstatutory\nrebates": "â¬ 398.34"
        },
        {
          "Designation of the\ntherapy": "Vinorelbine 10 mg",
          "Packaging\nsize": "10 CIS",
          "Costs\n(pharmacy\nsales price)": "â¬ 293.98",
          "Rebate\nSection\n130 SGB\nV": "â¬ 2.00",
          "Rebate\nSection\n130a\nSGB V": "â¬ 13.42",
          "Costs after\ndeduction of\nstatutory\nrebates": "â¬ 278.56"
        },
        {
          "Designation of the\ntherapy": "Vinorelbine 50 mg",
          "Packaging\nsize": "10 CIS",
          "Costs\n(pharmacy\nsales price)": "â¬ 1,424.53",
          "Rebate\nSection\n130 SGB\nV": "â¬ 2.00",
          "Rebate\nSection\n130a\nSGB V": "â¬ 67.07",
          "Costs after\ndeduction of\nstatutory\nrebates": "â¬ 1,355.46"
        },
        {
          "Designation of the\ntherapy": "Abbreviations: FCT = film-coated tablets, HC = hard capsules, CIS = concentrate for the preparation\nof an infusion solution, PIS = powder for the preparation of an infusion suspension; SC = soft\ncapsules"
        }
      ]
    },
    {
      "page": 23,
      "table": [
        {
          "Designation of the": "therapy"
        }
      ]
    },
    {
      "page": 23,
      "table": [
        {
          "Packaging": "size"
        }
      ]
    },
    {
      "page": 23,
      "table": [
        {
          "Costs": "(pharmacy"
        },
        {
          "Costs": "sales price)"
        }
      ]
    },
    {
      "page": 23,
      "table": [
        {
          "Rebate": "Section"
        },
        {
          "Rebate": "130 SGB"
        },
        {
          "Rebate": "V"
        }
      ]
    },
    {
      "page": 23,
      "table": [
        {
          "Rebate": "Section"
        },
        {
          "Rebate": "130a"
        },
        {
          "Rebate": "SGB V"
        }
      ]
    },
    {
      "page": 23,
      "table": [
        {
          "Costs after": "deduction of"
        },
        {
          "Costs after": "statutory"
        },
        {
          "Costs after": "rebates"
        }
      ]
    },
    {
      "page": 23,
      "table": [
        {
          "Designation of\nthe therapy": "Medicinal product to be assessed: Sotorasib"
        },
        {
          "Designation of\nthe therapy": "Not applicable"
        },
        {
          "Designation of\nthe therapy": "Appropriate comparator therapy:"
        },
        {}
      ]
    },
    {
      "page": 23,
      "table": [
        {
          "Designation of": "the therapy"
        }
      ]
    },
    {
      "page": 23,
      "table": [
        {
          "Packaging": "size"
        }
      ]
    },
    {
      "page": 23,
      "table": [
        {
          "Costs": "(pharmacy"
        },
        {
          "Costs": "sales price)"
        }
      ]
    },
    {
      "page": 23,
      "table": [
        {
          "Rebate": "Section"
        },
        {
          "Rebate": "130"
        },
        {
          "Rebate": "SGB V"
        }
      ]
    },
    {
      "page": 23,
      "table": [
        {
          "Rebate": "Section"
        },
        {
          "Rebate": "130a"
        },
        {
          "Rebate": "SGB V"
        }
      ]
    },
    {
      "page": 23,
      "table": [
        {
          "Costs after": "deduction"
        },
        {
          "Costs after": "of statutory"
        },
        {
          "Costs after": "rebates"
        }
      ]
    },
    {
      "page": 23,
      "table": [
        {
          "Treatment": "days/ year"
        }
      ]
    },
    {
      "page": 23,
      "table": [
        {
          "Costs/": "patient/"
        },
        {
          "Costs/": "year"
        }
      ]
    },
    {
      "page": 24,
      "table": [
        {
          "Designation of\nthe therapy": "Dexamethasone8\n,9\n(2 x 4 mg P.O.)",
          "Packaging\nsize": "100 TAB\n4 mg each",
          "Costs\n(pharmacy\nsales price)": "â¬ 79.50",
          "Rebate\nSection\n130\nSGB V": "â¬ 2.00",
          "Rebate\nSection\n130a\nSGB V": "â¬ 5.40",
          "Costs after\ndeduction\nof statutory\nrebates": "â¬ 72.10",
          "Treatment\ndays/ year": "52.2",
          "Costs/\npatient/\nyear": "â¬ 75.27"
        },
        {
          "Designation of\nthe therapy": "Folic acid\n(350 â 1,000\nÎ¼g/day, p.o.)",
          "Packaging\nsize": "100 TAB\n400 Î¼g\neach",
          "Costs\n(pharmacy\nsales price)": "â¬ 16.89",
          "Rebate\nSection\n130\nSGB V": "â¬ 0.84",
          "Rebate\nSection\n130a\nSGB V": "â¬ 2.13",
          "Costs after\ndeduction\nof statutory\nrebates": "â¬ 13.92",
          "Treatment\ndays/ year": "365.0",
          "Costs/\npatient/\nyear": "â¬ 50.81 -\nâ¬ 101.62"
        },
        {
          "Designation of\nthe therapy": "Vitamin B128\n(1,000 Î¼g/day,\nevery 3 cycles,\nIM)",
          "Packaging\nsize": "10 AMP\n1000 Î¼g\neach",
          "Costs\n(pharmacy\nsales price)": "â¬ 7.40",
          "Rebate\nSection\n130\nSGB V": "â¬ 0.37",
          "Rebate\nSection\n130a\nSGB V": "â¬ 0.32",
          "Costs after\ndeduction\nof statutory\nrebates": "â¬ 6.71",
          "Treatment\ndays/ year": "5.8",
          "Costs/\npatient/\nyear": "â¬ 3.89"
        },
        {
          "Designation of\nthe therapy": "Abbreviations: TAB = tablets; AMP = ampoules"
        }
      ]
    },
    {
      "page": 24,
      "table": [
        {
          "Designation of": "the therapy"
        }
      ]
    },
    {
      "page": 24,
      "table": [
        {
          "Packaging": "size"
        }
      ]
    },
    {
      "page": 24,
      "table": [
        {
          "Costs": "(pharmacy"
        },
        {
          "Costs": "sales price)"
        }
      ]
    },
    {
      "page": 24,
      "table": [
        {
          "Rebate": "Section"
        },
        {
          "Rebate": "130"
        },
        {
          "Rebate": "SGB V"
        }
      ]
    },
    {
      "page": 24,
      "table": [
        {
          "Rebate": "Section"
        },
        {
          "Rebate": "130a"
        },
        {
          "Rebate": "SGB V"
        }
      ]
    },
    {
      "page": 24,
      "table": [
        {
          "Costs after": "deduction"
        },
        {
          "Costs after": "of statutory"
        },
        {
          "Costs after": "rebates"
        }
      ]
    },
    {
      "page": 24,
      "table": [
        {
          "Treatment": "days/ year"
        }
      ]
    },
    {
      "page": 24,
      "table": [
        {
          "Costs/": "patient/"
        },
        {
          "Costs/": "year"
        }
      ]
    }
  ]
}